Previous 10 | Next 10 |
IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results PR Newswire ICESECRET study interim findings presented at the Urological Association Conference in Eilat, Israel ProSense ...
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors PR Newswire Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel , Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd . (N...
IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights PR Newswire Conference call is scheduled for 8:00 a.m. EST today with guest speaker Dr. Hania Bednarski , oncoplastic breast ...
IceCure's ProSense Featured in Poster Presentation at Radiological Society of North America's 2022 Annual Meeting PR Newswire Dr. Kenneth Tomkovich Presents: "To Freeze Or Not To Freeze? That Is The Question: Cryoablation For The Treatment Of Breast Cancer" Inc...
TIME CHANGE: IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022 PR Newswire CAESAREA, Israel , Nov. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) ...
IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022 PR Newswire CAESAREA, Israel , Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd . (NASDAQ: ICCM) (TASE: ICCM) ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock IceCure Medical (NASDAQ: ICCM ) stock is taking off on Tuesday as investors react to an update for Medicare coverage of breast cancer patients . The big news investors need to know about ...
IceCure Medical ( NASDAQ: ICCM ) stock rose ~44% on Tuesday after the company said its ProSense system for breast cancer cryoablation procedures was assigned to a Medicare payment group for hospital outpatient payment. The Centers for Medicare & Medicaid Ser...
IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures PR Newswire Receives assignment to a Medicare Payment Group for hospital outpatient payment Marks CMS's first payment assignment for cryoablation of...
IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month PR Newswire ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...